JP6289378B2 - ブプレノルフィンを含む経皮送達システム - Google Patents

ブプレノルフィンを含む経皮送達システム Download PDF

Info

Publication number
JP6289378B2
JP6289378B2 JP2014546672A JP2014546672A JP6289378B2 JP 6289378 B2 JP6289378 B2 JP 6289378B2 JP 2014546672 A JP2014546672 A JP 2014546672A JP 2014546672 A JP2014546672 A JP 2014546672A JP 6289378 B2 JP6289378 B2 JP 6289378B2
Authority
JP
Japan
Prior art keywords
buprenorphine
milligrams
transdermal therapeutic
therapeutic system
sensitive adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014546672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500329A5 (enExample
JP2015500329A (ja
Inventor
トーマス・ヒレ
ガブリエル・ワウワー
ケヴィン・ジョン・スミス
ジリアン・エリザベス・マンディン
ヘレン・エリザベス・ジョンソン
Original Assignee
エルテーエス ローマン テラピー−ジステーメ アーゲー
エルテーエス ローマン テラピー−ジステーメ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47754872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6289378(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エルテーエス ローマン テラピー−ジステーメ アーゲー, エルテーエス ローマン テラピー−ジステーメ アーゲー filed Critical エルテーエス ローマン テラピー−ジステーメ アーゲー
Publication of JP2015500329A publication Critical patent/JP2015500329A/ja
Publication of JP2015500329A5 publication Critical patent/JP2015500329A5/ja
Application granted granted Critical
Publication of JP6289378B2 publication Critical patent/JP6289378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014546672A 2011-12-12 2012-12-12 ブプレノルフィンを含む経皮送達システム Active JP6289378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569609P 2011-12-12 2011-12-12
US61/569,609 2011-12-12
PCT/IB2012/002973 WO2013088254A1 (en) 2011-12-12 2012-12-12 Transdermal delivery system comprising buprenorphine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016198650A Division JP2017036304A (ja) 2011-12-12 2016-10-07 ブプレノルフィンを含む経皮送達システム

Publications (3)

Publication Number Publication Date
JP2015500329A JP2015500329A (ja) 2015-01-05
JP2015500329A5 JP2015500329A5 (enExample) 2015-03-12
JP6289378B2 true JP6289378B2 (ja) 2018-03-07

Family

ID=47754872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546672A Active JP6289378B2 (ja) 2011-12-12 2012-12-12 ブプレノルフィンを含む経皮送達システム
JP2016198650A Pending JP2017036304A (ja) 2011-12-12 2016-10-07 ブプレノルフィンを含む経皮送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016198650A Pending JP2017036304A (ja) 2011-12-12 2016-10-07 ブプレノルフィンを含む経皮送達システム

Country Status (26)

Country Link
US (4) US20140363487A1 (enExample)
EP (1) EP2790685B2 (enExample)
JP (2) JP6289378B2 (enExample)
KR (1) KR102014565B1 (enExample)
CN (2) CN104114161A (enExample)
AP (1) AP4036A (enExample)
AR (1) AR089201A1 (enExample)
AU (1) AU2012327247B2 (enExample)
BR (1) BR112014014137A8 (enExample)
CA (1) CA2858531C (enExample)
CL (1) CL2014001559A1 (enExample)
CO (1) CO7000779A2 (enExample)
CR (1) CR20140321A (enExample)
DE (1) DE112012005185T5 (enExample)
EA (1) EA201491164A1 (enExample)
ES (1) ES2647516T3 (enExample)
GB (1) GB2512007B8 (enExample)
IL (1) IL233025A0 (enExample)
MX (1) MX352795B (enExample)
PE (1) PE20142341A1 (enExample)
PH (1) PH12014501231A1 (enExample)
PL (1) PL2790685T3 (enExample)
SG (2) SG11201403162XA (enExample)
TN (1) TN2014000233A1 (enExample)
TW (1) TW201338813A (enExample)
WO (1) WO2013088254A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856196C (en) 2011-12-06 2020-09-01 Masco Corporation Of Indiana Ozone distribution in a faucet
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AP2015008920A0 (en) * 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
CN106456566B (zh) 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
WO2017112795A1 (en) 2015-12-21 2017-06-29 Delta Faucet Company Fluid delivery system including a disinfectant device
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
GB201716830D0 (en) 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
US20210000756A1 (en) 2018-03-13 2021-01-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
US20210038532A1 (en) 2018-03-13 2021-02-11 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
CN111971033A (zh) 2018-03-13 2020-11-20 罗曼治疗系统股份公司 包含有机硅丙烯酸杂化聚合物的透皮治疗系统
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法
CN114397411A (zh) * 2021-12-14 2022-04-26 苏州高迈药业有限公司 一种评价利丙双卡因乳膏的方法
WO2024040897A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 沙利度胺或其类似物透皮贴剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119585A (en) * 1871-10-03 Improvement in horse-collars and hames
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
DE3939376C1 (enExample) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) † 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) † 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
DE4446600A1 (de) † 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19958554C2 (de) 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
CN1195505C (zh) 1999-07-02 2005-04-06 Lts勒曼治疗系统股份公司 以聚硅氧烷及亲两性溶剂为基础的微贮存系统
WO2001014336A1 (en) * 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives substituted by aromatic ring and process for producing the same
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6844727B2 (en) * 2000-06-28 2005-01-18 Baker Hughes Incorporated Method and apparatus of reducing ringing in a nuclear magnetic resonance probe
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (en) 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
EP1526848B1 (de) * 2002-08-09 2007-07-18 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
DK1572167T3 (da) * 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) † 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP2366388A1 (de) 2010-03-17 2011-09-21 Ratiopharm GmbH Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
EA201491164A1 (ru) 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
AP2015008920A0 (en) 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system

Also Published As

Publication number Publication date
AU2012327247A1 (en) 2013-06-27
US20160120823A1 (en) 2016-05-05
AP4036A (en) 2017-02-22
AU2012327247B2 (en) 2015-12-24
GB201412385D0 (en) 2014-08-27
KR20140101858A (ko) 2014-08-20
CR20140321A (es) 2014-11-13
JP2017036304A (ja) 2017-02-16
US9549903B2 (en) 2017-01-24
GB2512007B (en) 2017-04-26
BR112014014137A2 (pt) 2017-06-13
MX352795B (es) 2017-12-07
CA2858531C (en) 2019-12-17
KR102014565B1 (ko) 2019-08-26
ES2647516T3 (es) 2017-12-22
AP2014007779A0 (en) 2014-07-31
GB2512007A (en) 2014-09-17
GB2512007B8 (en) 2017-06-28
CL2014001559A1 (es) 2014-10-03
PL2790685T3 (pl) 2018-04-30
PE20142341A1 (es) 2015-01-17
TN2014000233A1 (en) 2015-09-30
MX2014007020A (es) 2014-07-14
EP2790685B1 (en) 2017-08-16
TW201338813A (zh) 2013-10-01
EP2790685A1 (en) 2014-10-22
CN104114161A (zh) 2014-10-22
CO7000779A2 (es) 2014-07-21
BR112014014137A8 (pt) 2017-06-13
IL233025A0 (en) 2014-07-31
HK1203048A1 (en) 2015-10-16
EA201491164A1 (ru) 2014-10-30
EP2790685B2 (en) 2026-04-01
NZ626535A (en) 2017-02-24
US20200306204A1 (en) 2020-10-01
SG11201403162XA (en) 2014-10-30
AR089201A1 (es) 2014-08-06
US20170049713A1 (en) 2017-02-23
US20140363487A1 (en) 2014-12-11
SG10201604754VA (en) 2016-08-30
CA2858531A1 (en) 2013-06-20
GB2512007A8 (en) 2017-06-28
DE112012005185T5 (de) 2014-08-28
PH12014501231A1 (en) 2014-09-08
WO2013088254A1 (en) 2013-06-20
CN107669662A (zh) 2018-02-09
HK1201760A1 (en) 2015-09-11
JP2015500329A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
JP6289378B2 (ja) ブプレノルフィンを含む経皮送達システム
US20200253957A1 (en) Transdermal delivery system
JP2023022245A (ja) アセナピンを含有する経皮治療システム
JP7659589B2 (ja) シリコーンアクリルハイブリッドポリマーを含むグアンファシンの経皮投与のための経皮治療システム
KR20210022656A (ko) 아세나핀을 함유하는 경피 치료 시스템
HK1203048B (en) Transdermal delivery system comprising buprenorphine
NZ626535B2 (en) Transdermal delivery system comprising buprenorphine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161028

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180206

R150 Certificate of patent or registration of utility model

Ref document number: 6289378

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250